Abstract
IncobotulinumtoxinA is the third botulinum neurotoxin type A (BoNTA) to be approved for aesthetic use in the United States. This article introduces the new product with an overview of clinical applications and a discussion of the neurotoxin's molecular structure. The role and clinical relevance of complexing proteins in BoNTA products are discussed. Finally, incobotulinumtoxinA's mechanism of action is described.
Original language | English (US) |
---|---|
Pages (from-to) | 18S-22S |
Journal | Unknown Journal |
Volume | 33 |
Issue number | 1 Suppl |
DOIs | |
State | Published - Mar 2013 |
ASJC Scopus subject areas
- Surgery